DARZALEX ® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant

· Updated data from the Phase 3 ALCYONE study showed an overall survival benefit and continued improvement in progression-free survival after a median duration of follow-up of more than three years with DARZALEX®; results simultaneously published in The Lancet· DARZALEX® is the only CD38-directe d antibody to show an overall survival benefit in multiple myeloma· Additionally, follow-up data from the Phase 3 MAIA study showed significant progression-free survival benefit continuing for three years following DARZALEX® treatment
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news